Miao Beiliang, Wang Dianhong, Yu Li, Meng Xiangfei, Liu Shiyi, Gao Mengqi, Han Jiatong, Chen Zeliang, Li Ping, Liu Shiwei
Department of Nephrology and Endocrinology, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing 100102, China.
Graduate school of Tianjin Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
Microbiol Res. 2025 Mar;292:127987. doi: 10.1016/j.micres.2024.127987. Epub 2024 Nov 30.
Bacterial biofilms are one of the most relevant drivers of chronic and recurrent infections and a significant healthcare problem. Biofilms were formed by cross-linking of hydrophobic extracellular polymeric substances (EPS), such as proteins, polysaccharides, and eDNA, which were synthesized by bacteria themselves after adhesion and colonization on biological surfaces. They had the characteristics of dense structure and low drug permeability, leading to tolerance and resistance of biofilms to antibiotics and to host responses. Within a biofilm, microbial cells show increased tolerance to both immune system defense mechanisms and antimicrobials than the same cells in the planktonic state. It is one of the key reasons for the failure of traditional clinical drug to treat infectious diseases. Currently, no drugs are available to attack bacterial biofilms in the clinical setting. The development of novel preventive and therapeutic strategies is urgently needed to allow an effective management of biofilm-associated infections. Based on the properties of nanomaterials and biocompatibility, nanotechnology had the advantages of specific targeting, intelligent delivery and low toxicity, which could realize efficient intervention and precise treatment of biofilm-associated infections. In this paper, the mechanisms of bacterial biofilm resistance to antibiotics and host response tolerance were elaborated. Meanwhile, This paper highlighted multiple strategies of biofilms eradication based on nanotechnology. Nanotechnology can interfere with biofilm formation by destroying mature biofilm, modulating biofilm heterogeneity, inhibiting bacterial metabolism, playing antimicrobial properties, activating immunity and enhancing biofilm penetration, which is an important new anti-biofilm preparation. In addition, we presented the key challenges still faced by nanotechnology in combating bacterial biofilm infections. Utilization of nanotechnology safely and effectively should be further strengthened to confirm the safety aspects of their clinical application.
细菌生物膜是慢性和复发性感染的最重要驱动因素之一,也是一个重大的医疗保健问题。生物膜由疏水性细胞外聚合物(EPS)交联形成,如蛋白质、多糖和胞外DNA,这些物质是细菌在生物表面粘附和定植后自身合成的。它们具有结构致密、药物渗透性低的特点,导致生物膜对抗生素和宿主反应具有耐受性和抗性。在生物膜内,微生物细胞比浮游状态下的相同细胞对免疫系统防御机制和抗菌药物的耐受性更高。这是传统临床药物治疗传染病失败的关键原因之一。目前,临床上没有药物可用于攻击细菌生物膜。迫切需要开发新 的预防和治疗策略,以有效管理与生物膜相关的感染。基于纳米材料的特性和生物相容性,纳米技术具有特异性靶向、智能递送和低毒性等优点,可实现对生物膜相关感染的高效干预和精准治疗。本文阐述了细菌生物膜对抗生素的耐药机制和对宿主反应的耐受性。同时,本文重点介绍了基于纳米技术的多种生物膜根除策略。纳米技术可通过破坏成熟生物膜、调节生物膜异质性、抑制细菌代谢、发挥抗菌特性、激活免疫和增强生物膜渗透性来干扰生物膜形成,这是一种重要的新型抗生物膜制剂。此外,我们还介绍了纳米技术在对抗细菌生物膜感染方面仍然面临的关键挑战。应进一步加强纳米技术的安全有效利用,以确认其临床应用的安全性。